organizing committee  

Dietary Conjugated Linoleic Acid (CLA) as a Potential Treatment for Metabolic Bone Disease
Hope Weiler(1,2), Susan Austin(1), Shirley Fitzpatrick-Wong(1), Evan Nitschmann(2),
Neda Bankovic-Calic(2), Rebecca Mollard(1), Harold Aukema(1,2), Malcolm Ogborn(1,2)
Departments of Human Nutritional Sciences(1), and Pediatrics and Child Health(2), University of Manitoba, Winnipeg, Manitoba.

Metabolic bone disease is characterized by elevations in parathyroid hormone (PTH) along with elevated rates of bone turnover. This is a feature of chronic renal disease. Since release of PTH is dependent on prostaglandin E2 (PGE2) synthesis and CLA is known to reduce synthesis of PGE2, this study was conducted to examine if feeding conjugated linoleic acid (CLA) would suppress hyperparathyroidism and high turnover bone disease secondary to polycystic kidney disease (PKD). Fifty-two weanling male Han:SPRD-cy rats were randomized to identical diets supplemented with and without CLA (1% of dietary fat) for 8 weeks. Main outcome measurements were: kidney weight, urea nitrogen and creatinine clearance; parathyroid hormone (PTH), bone formation and resorption; and femur bone mass using dual energy x-ray absorptiometry. Serum PTH and bone turnover were elevated in PKD affected rats. CLA feeding resulted in attenuation of PTH levels in both affected and non-affected rats (by 60%), but did not alter bone formation and resorption. Bone mass was not affected by CLA. Reduction in PTH may open possibilities for CLA as an adjunctive therapy in secondary hyperparathyroidism.
This research was supported by grants from Dairy Farmers of Canada, The Childrenís Hospital Foundation of Manitoba Inc. and NSERC.

Back to the Abstract List


program and  general information
published proceedings of the workshop